<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">thealth</journal-id><journal-title-group><journal-title xml:lang="ru">Здравоохранение Таджикистана</journal-title><trans-title-group xml:lang="en"><trans-title>Health care of Tajikistan</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0514-2415</issn><publisher><publisher-name>Редакция журнала «Здравоохранение Таджикистана»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52888/0514-2515-2024-362-3-111-118</article-id><article-id custom-type="elpub" pub-id-type="custom">thealth-591</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Хроническая болезнь почек и сердечно-сосудистые заболевания: есть ли связь?</article-title><trans-title-group xml:lang="en"><trans-title>Chronic kidney disease and cardiovascular disease: is there a connection?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шукурова</surname><given-names>С. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Shukurova</surname><given-names>S. M.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рашидов</surname><given-names>И. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Rashidov</surname><given-names>I. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рашидов Исмоил Махмадалиевич – к.м.н., заведующий отделения нефрологии и гемодиализа ГУ НМЦ РТ «Шифобахш», ассистент кафедры внутренних болезней ТГМУ имени Абуали ибн Сино, докторант ГУ «Таджикский НИИ профилактической медицины».</p><p>Тел.: +992903508008</p></bio><bio xml:lang="en"><p>Ismoil M. Rashidov - Candidate of Medical Sciences; Head of Nephrology and Haemodialysis Department of the SI SMC RT ‘Shifobakhsh’, Assistant Lecturer at the Department of Internal Medicine of the SEI Avicenna Tajik State Medical University; doctoral student of the SI Tajik Research Institute of Preventive Medicine.</p><p>Tel.: +992903508008</p></bio><email xlink:type="simple">nefrontj@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГОУ «Институт последипломного образования в сфере здравоохранения Республики Таджикистан»</institution><country>Таджикистан</country></aff><aff xml:lang="en"><institution>SEI Institute of Postgraduate Education in the Field of Health of the Republic of Tajikistan</institution><country>Tajikistan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГУ «Таджикский научно-исследовательский институт профилактической медицины»; Таджикский государственный медицинский университет имени Абуали ибн Сино</institution><country>Таджикистан</country></aff><aff xml:lang="en"><institution>SI Tajik Research Institute of Preventive Medicine; SEI Tajik State Medical University named after Abuali ibn Sino</institution><country>Tajikistan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>30</day><month>10</month><year>2024</year></pub-date><volume>0</volume><issue>3</issue><fpage>111</fpage><lpage>118</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шукурова С.М., Рашидов И.М., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Шукурова С.М., Рашидов И.М.</copyright-holder><copyright-holder xml:lang="en">Shukurova S.M., Rashidov I.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.zdrav.tj/jour/article/view/591">https://www.zdrav.tj/jour/article/view/591</self-uri><abstract><p>Хроническая болезнь почек представляет собой растущее бремя для здоровья во всем мире. Хроническая болезнь почек и сердечно-сосудистые заболевания тесно взаимосвязаны, и заболевание одного органа вызывает дисфункцию другого, что в конечном итоге приводит к недостаточности обоих органов. Пациенты с терминальной стадией почечной недостаточности подвергаются гораздо более высокому риску смертности от сердечно-сосудистых заболеваний. Традиционными и взаимными факторами риска сердечно-сосудистых заболеваний и хронической болезни почек являются возраст, артериальная гипертензия, сахарный диабет, дислипидемия, употребление табака, семейный анамнез и мужской пол. В этом обзоре мы сосредоточимся на том, является ли ранняя хроническая болезнь почек важным фактором риска наличия, тяжести и прогрессирования сердечно-сосудистых заболеваний.</p></abstract><trans-abstract xml:lang="en"><p>Chronic kidney disease represents an increasing health burden worldwide. Chronic kidney disease and cardiovascular disease are closely interlinked, with dysfunction in one organ often causing dysfunction in the other, ultimately leading to the failure of both. Patients with end-stage renal disease are at significantly higher risk of mortality due to cardiovascular complications. Shared risk factors for both chronic kidney disease and cardiovascular disease include age, hypertension, diabetes mellitus, dyslipidemia, tobacco use, family history, and male gender. This review focuses on whether early-stage chronic kidney disease serves as an important risk factor for the presence, severity, and progression of cardiovascular disease.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая болезнь почек</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>почечная дисфункция</kwd><kwd>сердечная недостаточность</kwd><kwd>скорость клубочковой фильтрации</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic kidney disease</kwd><kwd>cardiovascular disease</kwd><kwd>renal dysfunction</kwd><kwd>heart failure</kwd><kwd>glomerular filtration rate</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Абдуллоев С.М. Клинико-эпидемиологические особенности и факторы риска развития хронической болезни почек в Республике Таджикистан / С.М. Абдуллоев, М.К. Гулов // Здравоохранение Таджикистана. – 2019. – №2. – С. 5-13.</mixed-citation><mixed-citation xml:lang="en">Abdulloev S.M. Kliniko-epidemiologicheskie osobennosti i faktory riska razvitiya khronicheskoy bolezni pochek v Respublike Tadzhikistan [Clinical and epidemiological features and risk factors of chronic kidney disease in the Republic of Tajikistan]. Zdravookhranenie Tadzhikistana – Healthcare of Tajikistan, 2019, No. 2, pp. 5-13.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Давыдов В.В. Профилактика прогрессирования хронической болезни почек у пациентов с острой декомпенсацией хронической сердечной недостаточности /В.В. Давыдов, Е.Л. Арехина // Российский кардиологический журнал. – 2019. – Т.24, №3. – С. 76-81.</mixed-citation><mixed-citation xml:lang="en">Davydov V.V. Profilaktika progressirovaniya khronicheskoy bolezni pochek u patsientov s ostroy dekompensatsiey khronicheskoy serdechnoy nedostatochnosti [Prevention of chronic kidney disease progression in patients with acute decompensation of chronic heart failure]. Rossiyskiy kardiologicheskiy zhurnal - Russian Journal of Cardiology, 2019, Vol. 24, No. 3, pp. 76-81.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Загидуллин Н.Ш. Особенности антикоагуляции при сочетании фибрилляции предсердий и хронической болезни почек / Н.Ш. Загидуллин, П.А. Давтян // Российский кардиологический журнал. – 2021. – Т.26, №3. – С. 4676.</mixed-citation><mixed-citation xml:lang="en">Zagidullin N.Sh. Osobennosti antikoagulyatsii pri sochetanii fibrillyatsii predserdiy i khronicheskoy bolezni pochek [Features of anticoagulation in the combination of atrial fibrillation and chronic kidney disease]. Rossiyskiy kardiologicheskiy zhurnal – Russian Journal of Cardiology, 2021, Vol. 26, No. 3, pp. 4676.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Зарудский А.А. Изучение поражения почек у пациентов с систолической хронической сердечной недостаточностью / А.А. Зарудский, В.И. Фетисова, И.Ю. Шкилева, и др. // Современные проблемы науки и образования. – 2018. – №5. – С. 1-8.</mixed-citation><mixed-citation xml:lang="en">Zarudskiy A.A. Izuchenie porazheniya pochek u patsientov s sistolicheskoy khronicheskoy serdechnoy nedostatochnostyu [Study of renal damage in patients with systolic chronic heart failure]. Sovremennye problemy nauki i obrazovaniya - Modern problems of science and education, 2018, No. 5, pp. 1-8.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Камышникова Л.А. Биомаркеры развития нежелательных сердечно-сосудистых событий при заболеваниях почек / Л.А. Камышникова, К.С. Горбачевская, О.А. Ефремова и др. // Архивъ внутренней медицины. – 2023. – Т.13, №4. – С. 253-262.</mixed-citation><mixed-citation xml:lang="en">Kamyshnikova L.A. Biomarkery razvitiya nezhelatelnykh serdechno-sosudistykh sobytiy pri zabolevaniyakh pochek [Biomarkers for the development of adverse cardiovascular events in kidney disease]. Arkhiv vnutrenney meditsiny - Archives of Internal Medicine, 2023, Vol. 13, No. 4, pp. 253-262.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев В.Ю. Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение / В.Ю. Мареев, И.В. Фомин, Ф.Т. Агеев, и др. // Кардиология. 2018. – Т.58, №6. – С. 8-158.</mixed-citation><mixed-citation xml:lang="en">Mareev V.Yu. Klinicheskie rekomendatsii OSSN-RKO-RNMOT. Serdechnaya nedostatochnost: khronicheskaya (KHSN) i ostraya dekompensirovannaya (ODSN). Diagnostika, profilaktika i lechenie [OSSN-RKO-RNMOT Clinical Guidelines. Heart failure: chronic (CHF) and acute decompensated heart failure (ADHF). Diagnosis, prevention and treatment]. Kardiologiya – Cardiology, 2018, Vol. 58 (S6), pp. 8-158.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Мацкевич С.А. Хроническая болезнь почек: кардиоренальные взаимоотношения / С. А. Мацкевич // Лечеб. дело. – 2019. – №1. – С. 4–10.</mixed-citation><mixed-citation xml:lang="en">Matskevich S.A. Khronicheskaya bolezn pochek: kardiorenalnye vzaimootnosheniya [Chronic kidney disease: cardiorenal relationships]. Lechebnoe delo – Medicine, 2019, No. 1, pp. 4–10.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Поляков Д.С. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА–ХСН. /Д.С. Поляков, И.В. Фомин, Ю.Н. Беленков и др.// Кардиология. – 2021. – Т.61, №4. – С. 4-14.</mixed-citation><mixed-citation xml:lang="en">Polyakov D.S. Khronicheskaya serdechnaya nedostatochnost v Rossiyskoy Federatsii: chto izmenilos za 20 let nablyudeniya? Rezultaty issledovaniya EPOKHA–KHSN [Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOHA-CHD study]. Kardiologiya – Cardiology, 2021, Vol. 61, No. 4, pp. 4-14.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Резник Е.В. Кардиоренальный синдром у больных с сердечной недостаточностью как этап кардиоренального континуума (часть I): определение, классификация, патогенез, диагностика, эпидемиология (обзор литературы) / Е.В. Резник, И. Г. Никитин // Арх. внутр. медицины. – 2019. ‒ Т.9, №1. – С. 5-22.</mixed-citation><mixed-citation xml:lang="en">Reznik E.V. Kardiorenalnyy sindrom u bolnykh s serdechnoy nedostatochnostyu kak etap kardiorenalnogo kontinuuma (chast I): opredelenie, klassifikatsiya, patogenez, diagnostika, epidemiologiya (obzor literatury) [Cardiorenal syndrome in patients with heart failure as a stage of the cardiorenal continuum (part I): definition, classification, pathogenesis, diagnosis, epidemiology (literature review)]. Arkhiv vnutrenney meditsiny - Archive of Internal Medicine, 2019, Vol. 9, No. 1, pp. 5-22.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Хадзегова А.Б. Функция почек при сердечной недостаточности — предиктор выбора блокаторов РААС / А.Б. Хадзегова // РМЖ. Медицинское обозрение. – 2023. – Т.7, №1. – С. 30-35.</mixed-citation><mixed-citation xml:lang="en">Khadzegova A.B. Funktsiya pochek pri serdechnoy nedostatochnosti — prediktor vybora blokatorov RAAS [Renal function in heart failure is a predictor of the choice of RAAS blockers]. Rossiyskiy meditsinskiy zhurnal. Meditsinskoe obozrenie – Russian Medical Journal. Medical review, 2023, Vol. 7, No. 1, pp. 30-35.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Шукурова С.М. Клинико-лабораторные предикторы прогрессирования хронической болезни почек / С.М. Шукурова, И.М. Рашидов, С.Д. Косимова // Здравоохранение Таджикистана. – 2021. – №2. – С. 98-104.</mixed-citation><mixed-citation xml:lang="en">Shukurova S.M. Kliniko-laboratornye prediktory progressirovaniya khronicheskoy bolezni pochek [Clinical and laboratory predictors of chronic kidney disease progression]. Zdravookhranenie Tadzhikistana Hralthcare of Tajikistan, 2021, No. 2, pp. 98-104.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Agrawal A., Naranjo M., Kanjanahattakij N. Cardiorenal syndrome in heart failure with preserved ejection fraction – an under-recognized clinical entity. Heart Failure Reviews, 2019, Vol. 24, pp. 421-437.</mixed-citation><mixed-citation xml:lang="en">Agrawal A., Naranjo M., Kanjanahattakij N. Cardiorenal syndrome in heart failure with preserved ejection fraction – an under-recognized clinical entity. Heart Failure Reviews, 2019, Vol. 24, pp. 421-437.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Argano C., Mirarchi L., Amodeo S. The Role of Vitamin D and Its Molecular Bases in Insulin Resistance, Diabetes, Metabolic Syndrome, and Cardiovascular Disease: State of the Art. International Journal of Molecular Sciences, 2023, Vol. 24 (20), pp. 15485.</mixed-citation><mixed-citation xml:lang="en">Argano C., Mirarchi L., Amodeo S. The Role of Vitamin D and Its Molecular Bases in Insulin Resistance, Diabetes, Metabolic Syndrome, and Cardiovascular Disease: State of the Art. International Journal of Molecular Sciences, 2023, Vol. 24 (20), pp. 15485.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Banerjee D., Rosano G., Herzog C.A. Management of Heart Failure Patient with CKD. Clinical Journal of the American Society of Nephrology, 2021, Vol.16, No. 7, pp. 1131-1139.</mixed-citation><mixed-citation xml:lang="en">Banerjee D., Rosano G., Herzog C.A. Management of Heart Failure Patient with CKD. Clinical Journal of the American Society of Nephrology, 2021, Vol.16, No. 7, pp. 1131-1139.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Butler J., Packer M., Filippatos G., Ferreira J.P. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal, 2022, Vol. 43, No. 5, pp. 416-426.</mixed-citation><mixed-citation xml:lang="en">Butler J., Packer M., Filippatos G., Ferreira J.P. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal, 2022, Vol. 43, No. 5, pp. 416-426.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chaitman B.R., Cyr D.D., Alexander K.P. Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial. Circulation: Cardiovascular Interventions, 2022, Vol. 15, No. 8, pp. e012103.</mixed-citation><mixed-citation xml:lang="en">Chaitman B.R., Cyr D.D., Alexander K.P. Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial. Circulation: Cardiovascular Interventions, 2022, Vol. 15, No. 8, pp. e012103.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C.Y., Zhou Y., Wang P. Elevated central venous pressure is associated with increased mortality and acute kidney injury in critically ill patients: A meta-analysis Critical Care, 2020, Vol. 24, pp. 1-8.</mixed-citation><mixed-citation xml:lang="en">Chen C.Y., Zhou Y., Wang P. Elevated central venous pressure is associated with increased mortality and acute kidney injury in critically ill patients: A meta-analysis Critical Care, 2020, Vol. 24, pp. 1-8.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ding W.Y., Potpara T.S., Blomström-Lundqvist C.I mpact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. European Journal of Clinical Investigation, 2022, Vol. 52, No. 6, pp. e13745.</mixed-citation><mixed-citation xml:lang="en">Ding W.Y., Potpara T.S., Blomström-Lundqvist C.I mpact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. European Journal of Clinical Investigation, 2022, Vol. 52, No. 6, pp. e13745.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gala-Błądzińska A., Romanek J., Mazur D. Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2. Cardiology Research and Practice, 2020, pp. 1-10.</mixed-citation><mixed-citation xml:lang="en">Gala-Błądzińska A., Romanek J., Mazur D. Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2. Cardiology Research and Practice, 2020, pp. 1-10.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Gembillo G., Ingrasciotta Y., Crisafulli S. Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. International Journal of Molecular Sciences, 2021, Vol. 22, pp. 4824.</mixed-citation><mixed-citation xml:lang="en">Gembillo G., Ingrasciotta Y., Crisafulli S. Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. International Journal of Molecular Sciences, 2021, Vol. 22, pp. 4824.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Khan M., Tahhan A., Vaduganathan M. Trends in prevalence of comorbidities in heart failure clinical trials. European Journal of Heart Failure, 2020, Vol. 22, pp.1032-1042.</mixed-citation><mixed-citation xml:lang="en">Khan M., Tahhan A., Vaduganathan M. Trends in prevalence of comorbidities in heart failure clinical trials. European Journal of Heart Failure, 2020, Vol. 22, pp.1032-1042.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Khunti K., Danese M.D., Kutikova L. Association of a Combined Measure of Adherence and Treatment Intensity with Cardiovascular Outcomes in Patients with Atherosclerosis or Other Cardiovascular Risk Factors Treated with Statins and/or Ezetimibe. Journal of the American Medical Association Network Open, 2018, Vol. 1, No. 8, pp. e185554.</mixed-citation><mixed-citation xml:lang="en">Khunti K., Danese M.D., Kutikova L. Association of a Combined Measure of Adherence and Treatment Intensity with Cardiovascular Outcomes in Patients with Atherosclerosis or Other Cardiovascular Risk Factors Treated with Statins and/or Ezetimibe. Journal of the American Medical Association Network Open, 2018, Vol. 1, No. 8, pp. e185554.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical practice guideline for the evaluation and Management of Chronic Kidney Disease. Kidney International Supplements, 2012, No. 3, pp.1-150.</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical practice guideline for the evaluation and Management of Chronic Kidney Disease. Kidney International Supplements, 2012, No. 3, pp.1-150.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo I.C., Wu P.H., Lin H.Y. The association of adiponectin with metabolic syndrome and clinical outcome in patients with non-diabetic chronic kidney disease. PLoS One, 2019, Vol. 14, No. 7, pp. e0220158.</mixed-citation><mixed-citation xml:lang="en">Kuo I.C., Wu P.H., Lin H.Y. The association of adiponectin with metabolic syndrome and clinical outcome in patients with non-diabetic chronic kidney disease. PLoS One, 2019, Vol. 14, No. 7, pp. e0220158.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Mann M.C., Hobbs A.J., Hemmelgarn B.R. Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clinical Kidney Journal, 2015, Vol. 8, No. 1, pp. 41-48.</mixed-citation><mixed-citation xml:lang="en">Mann M.C., Hobbs A.J., Hemmelgarn B.R. Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clinical Kidney Journal, 2015, Vol. 8, No. 1, pp. 41-48.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mullens W., Damman K., Testani J.M. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, Vol. 22, No. 4, pp. 584-603.</mixed-citation><mixed-citation xml:lang="en">Mullens W., Damman K., Testani J.M. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, Vol. 22, No. 4, pp. 584-603.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Parker J., Hashmi O., Dutton D. Levels of vitamin D and cardiometabolic disorders: Systematic review and meta-analysis. Maturitas, 2010, Vol. 65, pp. 225-236.</mixed-citation><mixed-citation xml:lang="en">Parker J., Hashmi O., Dutton D. Levels of vitamin D and cardiometabolic disorders: Systematic review and meta-analysis. Maturitas, 2010, Vol. 65, pp. 225-236.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Rangaswami J., Bhalla V., Blair J.E. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement from the American Heart Association. Circulation, 2019, Vol. 139, pp. e840–e878.</mixed-citation><mixed-citation xml:lang="en">Rangaswami J., Bhalla V., Blair J.E. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement from the American Heart Association. Circulation, 2019, Vol. 139, pp. e840–e878.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Santoro D., Gembillo G., Andò G. Glomerular Filtration Rate as a Predictor of Outcome in Acute Coronary Syndrome Complicated by Atrial Fibrillation. Journal of Clinical Medicine, 2020, No. 9, pp.1466.</mixed-citation><mixed-citation xml:lang="en">Santoro D., Gembillo G., Andò G. Glomerular Filtration Rate as a Predictor of Outcome in Acute Coronary Syndrome Complicated by Atrial Fibrillation. Journal of Clinical Medicine, 2020, No. 9, pp.1466.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Singh N.P., Gupta A.K., Kaur G. Chronic Kidney Disease of Unknown Origin - What do we know? Journal of the Association of Physicians of India, 2020, Vol. 68, No. 2, pp. 76-79.</mixed-citation><mixed-citation xml:lang="en">Singh N.P., Gupta A.K., Kaur G. Chronic Kidney Disease of Unknown Origin - What do we know? Journal of the Association of Physicians of India, 2020, Vol. 68, No. 2, pp. 76-79.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Tarvasmäki T., Haapio M., Mebazaa A. Acute kidney injury in cardiogenic shock: Definitions, incidence, haemodynamic alterations, and mortality. European Journal of Heart Failure, 2018, Vol. 20, pp. 572-581.</mixed-citation><mixed-citation xml:lang="en">Tarvasmäki T., Haapio M., Mebazaa A. Acute kidney injury in cardiogenic shock: Definitions, incidence, haemodynamic alterations, and mortality. European Journal of Heart Failure, 2018, Vol. 20, pp. 572-581.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Yogasundaram H., Chappell M.C., Braam B. Cardiorenal Syndrome and Heart Failure – Challenges and Opportunities. Canadian Journal of Cardiology, 2019, Vol. 35, pp. 1208-1219.</mixed-citation><mixed-citation xml:lang="en">Yogasundaram H., Chappell M.C., Braam B. Cardiorenal Syndrome and Heart Failure – Challenges and Opportunities. Canadian Journal of Cardiology, 2019, Vol. 35, pp. 1208-1219.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
